Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC)
Tan, W Wilner, K Lanzalone, S Polli, A Zierhut, M Nickens, D O'Byrne, K Blackhall, Fiona H Shaw, A Salgia, R
Tan, W
Wilner, K
Lanzalone, S
Polli, A
Zierhut, M
Nickens, D
O'Byrne, K
Blackhall, Fiona H
Shaw, A
Salgia, R
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2015-08-02
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) 2015, 75 (15 Supplement):CT117 Cancer Res